Sage Journals: Discover world-class research

Abstract

Keywords

Pembrolizumab checkpoint inhibitors demyelination

Get full access to this article

View all access options for this article.

References

Wang

Kurra

Gainor

et al . Immune checkpoint inhibitor cancer therapy: Spectrum of imaging findings. Radiographics 2017; 37: 2132–2144.

Hottinger

AF.

Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 2016; 29: 806–812.

Durães

Coutinho

Mariano

et al . Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma. Mult Scler 2019; 25(7): 1005–1008.

Antonazzo

Raschi

Vignatelli

et al . Occurrence of multiple sclerosis after drug exposure: Insights from evidence mapping. Drug Saf 2017; 40: 823–834.

Mughal

Schrieber

Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biologics 2010; 4: 315–323.

Hidden cost of pembrolizumab therapy

Abstract

Keywords

Get full access to this article

References